Genetic Testing for Early Alzheimer's Disease Prevention
ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
Recruiting
Observational Study
Alzheimer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50,000 (estimated)
- Sponsor
- Firalis SA · Industry
Who this trial is looking for
This trial is looking for adults over 45 years old living in France who want to learn about their genetic risk for Alzheimer's disease. Participants will provide a saliva sample for testing and complete online assessments over time.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 45 years old.
- I live in France.
- I can read and understand the study information in French.
- I can electronically sign the consent form.
- I have access to the internet and a valid email address.
- I can self-collect and return a saliva sample using a provided kit.
You may not be able to join if
- I cannot sign the consent form.
- I am under 45 years old.
- I have known cognitive impairments or severe dementia.
- I have had a substance use disorder in the past 24 months.
- I cannot be contacted reliably by email or phone.
- I have previously participated in this trial.
- I am under guardianship or similar legal protection.
- I have a physical condition that prevents me from participating.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ALZEVIT is a nationwide, decentralized, digital-first cohort study in France designed to establish a large-scale Apolipoprotein E (APOE) genotyping registry and enable precision prevention strategies for Alzheimer's disease (AD). Sponsored by Firalis SA and conducted in collaboration with French memory centers, it addresses the need for early identification of individuals at high genetic risk, par…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants who sign the electronic Informed Consent form.
* Adults aged over 45 years old (inclusive) at the time of consent.
* Participants residing in France.
* Participants able to read and understand the study information in French or with the help of a legal representat…
Contacts